Prime Medicine, Inc.(PRME)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PRME Prime Medicine, Inc.

已收盘 10-28 16:00:00 EDT

5.36

+1.01

+23.22%

盘后5.18

-0.18-3.36%

19:58 EDT

最高5.43	最低4.11	成交量1,520万
今开4.24	昨收4.35	日振幅30.34%
总市值9.68亿	流通市值6.22亿	总股本1.81亿
成交额7,712万	换手率13.10%	流通股本1.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PRME","market":"US","secType":"STK","nameCN":"Prime Medicine, Inc.","latestPrice":5.36,"timestamp":1793217600000,"preClose":4.35,"halted":0,"volume":15200691,"hourTrading":{"tag":"盘后","latestPrice":5.18,"preClose":5.36,"latestTime":"19:58 EDT","volume":104225,"amount":550104.445002,"timestamp":1793231935002,"change":-0.18,"changeRate":-0.033582,"amplitude":0.048507},"delay":0,"changeRate":0.2321839080459772,"floatShares":115999999,"shares":180510658,"eps":-1.085332,"marketStatus":"已收盘","change":1.01,"latestTime":"10-28 16:00:00 EDT","open":4.24,"high":5.43,"low":4.11,"amount":77124434.5180023,"amplitude":0.303448,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.085332,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793260800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1666238400000,"exchange":"NASDAQ","adjPreClose":4.35,"preHourTrading":{"tag":"盘前","latestPrice":4.25,"preClose":4.35,"latestTime":"09:27 EDT","volume":11022,"amount":47221.874238,"timestamp":1793194060023,"change":-0.1,"changeRate":-0.022989,"amplitude":0.055172},"postHourTrading":{"tag":"盘后","latestPrice":5.18,"preClose":5.36,"latestTime":"19:58 EDT","volume":104225,"amount":550104.445002,"timestamp":1793231935002,"change":-0.18,"changeRate":-0.033582,"amplitude":0.048507},"volumeRatio":3.305126,"impliedVol":1.3354,"impliedVolPercentile":0.9163},"requestUrl":"/m/hq/s/PRME","defaultTab":"news","newsList":[{"id":"2670441624","title":"Prime Medicine（PRME）盘前涨10.45% FDA批准其PM647的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2670441624","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670441624?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:33","pubTimestamp":1790328824,"startTime":"0","endTime":"0","summary":"金吾财讯 | Prime Medicine（PRME）盘前涨10.45%，报3.391美元。消息面上，美国食品药品监督管理局（FDA）批准其PM647的新药临床试验申请（IND）。获批使Prime Medicine能够启动一项评估PM647用于患有该遗传性疾病成人患者的1/2期试验。预计将于2027年获得初步临床数据。PM647是一种用于治疗α-1抗胰蛋白酶缺乏症的实验性基因编辑疗法。PM647旨在修复导致α-1抗胰蛋白酶缺乏症的基因突变。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306480","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IBBJ","LABU","PSYK","MDTX","BK4139","IBBQ","PRME","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166369496","title":"Prime Medicine 预计截至2026年6月30日现金与投资足以支撑运营至2027年","url":"https://stock-news.laohu8.com/highlight/detail?id=1166369496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166369496?lang=zh_cn&edition=full","pubTime":"2026-08-06 21:01","pubTimestamp":1786021270,"startTime":"0","endTime":"0","summary":"Prime Medicine, Inc. 预计，截至2026年6月30日，公司持有的现金及投资将足以支撑其运营，直至2027年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103840308","title":"Prime Medicine, Inc. 第二季度每股亏损0.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103840308","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103840308?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:14","pubTimestamp":1786018492,"startTime":"0","endTime":"0","summary":"8月6日，Prime Medicine, Inc. 公布其第二季度运营支出为4443.9万美元。由此，该公司每股收益录得亏损0.24美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654010113","title":"错峰抄底重仓特斯拉 木头姐ARK Invest完成全品类持仓调仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2654010113","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654010113?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:12","pubTimestamp":1785154356,"startTime":"0","endTime":"0","summary":"金吾财讯｜凯茜·伍德旗下ARK Invest完成大规模双向调仓操作，整体延续聚焦AI、自动驾驶、太空科技、创新医疗、金融科技的核心投资主线，在多赛道加码优质标的，同时对部分科技、工业、医疗标的获利减持，持仓结构进一步优化。本期最大手笔增持为特斯拉，在特斯拉二季度财报不及预期、单日暴跌约15%创下一年最大单日跌幅后，ARK Invest逆势加仓价值5270万美元的特斯拉股票。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303054","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLA","TWST","IRDM","ROKU","SHOP","FIG","SHPD","SRTA","LLY","ARKQ","MAGY","ARKB","BIDU","ACHR","AMD","META","NTRA","SARK","ARKF","ESLT","TSLL","VEGI","ARKK","CRCL","IXJ","PRME","ABSI","BULZ","CAT","TEM","SMH","YMAG","ATAI","ILMN","CDNA","ARKW","AMDL","OGIG","HOOD","ARKG","CMPS","SNOW","TXG","SCTX","XE","DE","TER","LTL","ARKX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1166762271","title":"Prime Medicine宣布美国FDA批准Pm577a治疗H1069q突变型威尔逊病的新药临床申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1166762271","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166762271?lang=zh_cn&edition=full","pubTime":"2026-07-24 04:06","pubTimestamp":1784837175,"startTime":"0","endTime":"0","summary":"Prime Medicine（Prime Medicine, Inc.）今日宣布，美国食品药品监督管理局（FDA）已批准其针对H1069q突变型威尔逊病候选药物Pm577a的研究性新药申请（IND）。这一里程碑式的进展，标志着该公司在基因编辑疗法领域迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143598675","title":"仲裁庭确认Prime Medicine拥有开发和商业化Pm647用于AATD的权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1143598675","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143598675?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:03","pubTimestamp":1783512204,"startTime":"0","endTime":"0","summary":"仲裁庭已正式确认，Prime Medicine, Inc. 拥有开发和商业化其候选药物Pm647用于治疗α-1抗胰蛋白酶缺乏症（AATD）的权利。这一决定解决了围绕该药物权益的潜在争议，为该公司推进该治疗项目扫清了关键的法律障碍。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130410441","title":"Prime Medicine 旗下 PM359 获美 FDA 再生医学先进疗法认定，用于治疗慢性肉芽肿病","url":"https://stock-news.laohu8.com/highlight/detail?id=1130410441","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130410441?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:01","pubTimestamp":1782129682,"startTime":"0","endTime":"0","summary":"Prime Medicine 公司宣布，其用于治疗慢性肉芽肿病的在研疗法 PM359 已获得美国食品药品监督管理局授予的再生医学先进疗法认定。这一认定旨在加速针对严重疾病且初步临床证据显示有潜力满足未竟医疗需求的再生医学疗法的开发与审评。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138506537","title":"Prime Medicine公司宣布Pm577a针对H1069q突变型威尔逊病的临床试验申请获新西兰批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1138506537","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138506537?lang=zh_cn&edition=full","pubTime":"2026-06-18 20:03","pubTimestamp":1781784186,"startTime":"0","endTime":"0","summary":"Prime Medicine公司宣布，其针对H1069q突变型威尔逊病的候选疗法Pm577a的临床试验申请，已获得新西兰监管机构的批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518782227","title":"Prime Medicine, Inc.盘中异动 早盘股价大跌5.00%报2.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518782227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518782227?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:35","pubTimestamp":1741613718,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时35分，Prime Medicine, Inc.股票出现波动，股价大幅下挫5.00%。Prime Medicine, Inc.股票所在的生物技术行业中，整体涨幅为0.07%。Prime Medicine, Inc.公司简介：Prime Medicine Inc 是一家生物技术公司，致力于通过部署基因编辑技术 Prime Editing 提供基因疗法来治疗疾病。Prime Editing技术是一种可以通过搜索和替换来恢复基因组中正常遗传功能，可以治疗具有高度未满足医疗需求的广泛疾病和高效广泛的基因编辑技术的下一代技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021351998a29db8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021351998a29db8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518996447","title":"Prime Medicine, Inc.2024财年实现净利润-1.96亿美元，同比增加1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518996447","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518996447?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449656,"startTime":"0","endTime":"0","summary":"3月9日，Prime Medicine, Inc.公布财报，公告显示公司2024财年净利润为-1.96亿美元，同比增加1.01%；其中营业收入为2.98百万美元，每股基本收益为-1.65美元。从资产负债表来看，Prime Medicine, Inc.总负债3.37亿美元，其中短期债务3.61百万美元，资产负债比为1.46，流动比率为0.06。机构评级：截至2025年3月9日，当前有10家机构对Prime Medicine, Inc.目标价做出预测，其中目标均价为12.90美元，其中最低目标价为6.00美元，最高目标价为19.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000212abef97d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000212abef97d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517334924","title":"Prime Medicine, Inc.盘中异动 临近收盘股价大涨5.12%报2.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517334924","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517334924?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:55","pubTimestamp":1741208119,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时55分，Prime Medicine, Inc.股票出现异动，股价急速上涨5.12%。Prime Medicine, Inc.股票所在的生物技术行业中，整体涨幅为1.97%。Prime Medicine, Inc.公司简介：Prime Medicine Inc 是一家生物技术公司，致力于通过部署基因编辑技术 Prime Editing 提供基因疗法来治疗疾病。Prime Editing技术是一种可以通过搜索和替换来恢复基因组中正常遗传功能，可以治疗具有高度未满足医疗需求的广泛疾病和高效广泛的基因编辑技术的下一代技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306045519a261319d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306045519a261319d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516672350","title":"Citizens Capital Markets：重申Prime Medicine(PRME.US)评级，由优于大市调整至优于大市评级, 目标价由10.00美元调整至10.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516672350","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516672350?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:22","pubTimestamp":1741098129,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets：重申Prime Medicine(PRME.US)评级，由优于大市调整至优于大市评级, 目标价由10.00美元调整至10.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04222248521887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516653246","title":"Prime Medicine, Inc.盘中异动 股价大跌5.06%报2.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653246","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516653246?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:21","pubTimestamp":1741018880,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时21分，Prime Medicine, Inc.股票出现异动，股价大幅下挫5.06%。Prime Medicine, Inc.股票所在的生物技术行业中，整体跌幅为0.41%。Prime Medicine, Inc.公司简介：Prime Medicine Inc 是一家生物技术公司，致力于通过部署基因编辑技术 Prime Editing 提供基因疗法来治疗疾病。Prime Editing技术是一种可以通过搜索和替换来恢复基因组中正常遗传功能，可以治疗具有高度未满足医疗需求的广泛疾病和高效广泛的基因编辑技术的下一代技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304002120989a2a8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304002120989a2a8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516379709","title":"Prime Medicine, Inc.盘中异动 早盘股价大涨5.37%报2.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379709","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516379709?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:06","pubTimestamp":1740758766,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时06分，Prime Medicine, Inc.股票出现异动，股价快速拉升5.37%。Prime Medicine, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。Prime Medicine, Inc.公司简介：Prime Medicine Inc 是一家生物技术公司，致力于通过部署基因编辑技术 Prime Editing 提供基因疗法来治疗疾病。Prime Editing技术是一种可以通过搜索和替换来恢复基因组中正常遗传功能，可以治疗具有高度未满足医疗需求的广泛疾病和高效广泛的基因编辑技术的下一代技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000606abe100e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000606abe100e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146217215","title":"Prime Medicine 2024财年GAAP每股收益$(1.65)优于预期$(1.66)，销售额$2.983M超出预期$929.100K","url":"https://stock-news.laohu8.com/highlight/detail?id=1146217215","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146217215?lang=zh_cn&edition=full","pubTime":"2025-02-28 21:06","pubTimestamp":1740747970,"startTime":"0","endTime":"0","summary":"Prime Medicine 2024财年GAAP每股收益$(1.65)，优于预期$(1.66)，销售额$2.983M，超出预期$929.100K。以上内容来自Benzinga Earnings专栏，原文如下：Prime Medicine FY 2024 GAAP EPS $(1.65) Beats $(1.66) Estimate, Sales $2.983M Beats $929.100K Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Prime Medicine 2024财年GAAP每股收益$(1.65)优于预期$(1.66)，销售额$2.983M超出预期$929.100K","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514386789","title":"Prime Medicine, Inc.盘中异动 早盘急速拉升5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514386789","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514386789?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:47","pubTimestamp":1740667672,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时47分，Prime Medicine, Inc.股票出现波动，股价急速上涨5.48%。Prime Medicine, Inc.股票所在的生物技术行业中，整体涨幅为0.80%。Prime Medicine, Inc.公司简介：Prime Medicine Inc 是一家生物技术公司，致力于通过部署基因编辑技术 Prime Editing 提供基因疗法来治疗疾病。Prime Editing技术是一种可以通过搜索和替换来恢复基因组中正常遗传功能，可以治疗具有高度未满足医疗需求的广泛疾病和高效广泛的基因编辑技术的下一代技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224752abdf72d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224752abdf72d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514622138","title":"Prime Medicine, Inc.盘中异动 临近收盘股价大跌5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514622138","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514622138?lang=zh_cn&edition=full","pubTime":"2025-02-27 04:42","pubTimestamp":1740602539,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日04时42分，Prime Medicine, Inc.股票出现异动，股价快速跳水5.28%。Prime Medicine, Inc.股票所在的生物技术行业中，整体跌幅为0.72%。Prime Medicine, Inc.公司简介：Prime Medicine Inc 是一家生物技术公司，致力于通过部署基因编辑技术 Prime Editing 提供基因疗法来治疗疾病。Prime Editing技术是一种可以通过搜索和替换来恢复基因组中正常遗传功能，可以治疗具有高度未满足医疗需求的广泛疾病和高效广泛的基因编辑技术的下一代技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022704421996319069&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022704421996319069&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514016658","title":"Prime Medicine, Inc.盘中异动 股价大跌5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514016658","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514016658?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:47","pubTimestamp":1740498439,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时47分，Prime Medicine, Inc.股票出现波动，股价大幅跳水5.14%。Prime Medicine, Inc.股票所在的生物技术行业中，整体涨幅为0.79%。Prime Medicine, Inc.公司简介：Prime Medicine Inc 是一家生物技术公司，致力于通过部署基因编辑技术 Prime Editing 提供基因疗法来治疗疾病。Prime Editing技术是一种可以通过搜索和替换来恢复基因组中正常遗传功能，可以治疗具有高度未满足医疗需求的广泛疾病和高效广泛的基因编辑技术的下一代技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022523471998925d46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022523471998925d46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513077331","title":"Prime Medicine, Inc.盘中异动 快速下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513077331","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513077331?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:39","pubTimestamp":1740411587,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时39分，Prime Medicine, Inc.股票出现波动，股价急速下跌5.06%。Prime Medicine, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Prime Medicine, Inc.公司简介：Prime Medicine Inc 是一家生物技术公司，致力于通过部署基因编辑技术 Prime Editing 提供基因疗法来治疗疾病。Prime Editing技术是一种可以通过搜索和替换来恢复基因组中正常遗传功能，可以治疗具有高度未满足医疗需求的广泛疾病和高效广泛的基因编辑技术的下一代技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224233947abdb1dfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224233947abdb1dfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513460212","title":"Prime Medicine, Inc.盘中异动 快速下挫5.11%报2.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513460212","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513460212?lang=zh_cn&edition=full","pubTime":"2025-02-22 04:47","pubTimestamp":1740170847,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日04时47分，Prime Medicine, Inc.股票出现异动，股价快速下跌5.11%。Prime Medicine, Inc.股票所在的生物技术行业中，整体涨幅为0.32%。Prime Medicine, Inc.公司简介：Prime Medicine Inc 是一家生物技术公司，致力于通过部署基因编辑技术 Prime Editing 提供基因疗法来治疗疾病。Prime Editing技术是一种可以通过搜索和替换来恢复基因组中正常遗传功能，可以治疗具有高度未满足医疗需求的广泛疾病和高效广泛的基因编辑技术的下一代技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222044727a24efdde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222044727a24efdde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.primemedicine.com;investors.primemedicine.com","stockEarnings":[{"period":"1week","weight":0.1097},{"period":"1month","weight":0.5},{"period":"3month","weight":0.4356},{"period":"6month","weight":0.2271},{"period":"1year","weight":-0.1553},{"period":"ytd","weight":0.2536}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0551},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1232},{"period":"ytd","weight":0.1287}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Prime Medicine, Inc.于2019年9月在特拉华州注册成立。该公司是一家生物技术公司，致力于提供一类新的差异化一次性治疗基因疗法— Prime Editors，通过部署Prime Editing技术来解决最广泛的疾病谱。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070058},{"month":2,"riseRate":0.5,"avgChangeRate":0.101559},{"month":3,"riseRate":0,"avgChangeRate":-0.224329},{"month":4,"riseRate":0.5,"avgChangeRate":-0.072402},{"month":5,"riseRate":0.5,"avgChangeRate":-0.000767},{"month":6,"riseRate":0.75,"avgChangeRate":0.248413},{"month":7,"riseRate":0.75,"avgChangeRate":0.106402},{"month":8,"riseRate":0.25,"avgChangeRate":-0.065687},{"month":9,"riseRate":0.25,"avgChangeRate":0.046401},{"month":10,"riseRate":0.5,"avgChangeRate":-0.000383},{"month":11,"riseRate":0.25,"avgChangeRate":-0.086687},{"month":12,"riseRate":0.5,"avgChangeRate":0.02429}],"exchange":"NASDAQ","name":"Prime Medicine, Inc.","nameEN":"Prime Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Prime Medicine, Inc.(PRME)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Prime Medicine, Inc.(PRME)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Prime Medicine, Inc.,PRME,Prime Medicine, Inc.股票,Prime Medicine, Inc.股票老虎,Prime Medicine, Inc.股票老虎国际,Prime Medicine, Inc.行情,Prime Medicine, Inc.股票行情,Prime Medicine, Inc.股价,Prime Medicine, Inc.股市,Prime Medicine, Inc.股票价格,Prime Medicine, Inc.股票交易,Prime Medicine, Inc.股票购买,Prime Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Prime Medicine, Inc.(PRME)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Prime Medicine, Inc.(PRME)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}